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Cardiac resynchronization therapy (CRT) is an established treatment for symptomatic patients with heart failure, a prolonged QRS duration,
and impaired left ventricular (LV) function. Identiﬁcation of ‘responders’ and ‘non-responders’ to CRT has attracted considerable attention.
The response to CRT can be measured in terms of symptomatic response or clinical outcome, or both. Alternatively, the response to CRT
can be measured in terms of changes in surrogate measures of outcome, such as LV volumes, LV ejection fraction, invasive measures of
cardiac performance, peak oxygen uptake, and neurohormones. This review explores whether these measures can be used in assessing
the symptomatic and prognostic response to CRT. The role of these parameters to the management of individual patients is also discussed.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Cardiac resynchronization therapy (CRT) was unveiled as a new
therapy by the pioneering work of Cazeau et al.
1 who, in 1994,
reported the dramatic clinical improvement of a 54-year-old man
in severe heart failure treated by four-chamber pacing. Later in
an acute study, Leclercq et al.
2 showed that temporary CRT
increases left ventricular (LV) stroke volume and reduces pulmon-
ary capillary wedge pressure. Auricchio’s group, further, showed
that CRT increases LV dP/dt.
3 In 2001, the Multisite Stimulation
in Cardiomyopathies (MUSTIC) study, in the ﬁrst randomized con-
trolled cross-over trial design in the ﬁeld of resynchronization
therapy, found that CRT dramatically reduced heart failure hospi-
talizations and improved NYHA class, as well as quality of life,
exercise distance, and peak oxygen uptake (peak VO2).
4 More
recently, the Cardiac Resynchronization in Heart Failure
(CARE-HF) trial indicated that CRT-pacing (CRT-P) led to a 36%
relative reduction in total mortality compared with medical
therapy.
5 The comparison of medical therapy, pacing, and deﬁbril-
lation in heart failure (COMPANION) study showed that addition
of a cardioverter deﬁbrillator (CRT-D) to CRT also led to
additional survival beneﬁts compared with CRT-P.
6
Response to CRT has become critically important as it is con-
sidered in a different way from that with drug therapy of heart
failure. With drugs, patients are up-titrated to the doses used in
major outcome trials without the need for measuring symptomatic
response or predictors of outcome in routine clinical settings.
Possibly, the insistence on deﬁning CRT response in the same set-
tings reﬂects both the high initial cost of the pacing system and the
need for a surgical procedure to implant it. If measurement of
response and outcome in CRT is necessary, outcome variables
must surely provide ‘a valid and reliable measure of some clinically
relevant and important treatment beneﬁt in the patient popu-
lation’.
7 Ultimately, the ﬁnal objective must be to prolong survival
and/or to alleviate symptoms as well as to improve quality of life.
This review focuses on parameters that have so far been used to
deﬁne a response to CRT. The relevance of these parameters to
the management of individual patients is also discussed.
Outcome and response
Outcome
In order to estimate the effects of CRT on survival, patients’ life-
times must be considered rather than the follow-up period of a
study. The 2007 United Kingdom National Institute of Clinical
Excellence (NICE) Health Technology Appraisal (HTA) on CRT
provided an extensive analysis of CRT-P, CRT-D, and optimum
pharmacological therapy (OPT) alone over patients’ lifetimes
(Table 1).
8 According to these analyses, the median survival after
device implantation is 4.62 years for CRT-P and 5.15 years for
CRT-D. However, the additional life gained must be compared
with OPT and amounts to a median of 0.85 years for CRT-P and
1.39 years for CRT-D.
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characteristics inﬂuence the outcome of CRT.
8 Age at the time of
implantation, for example, has a signiﬁcant impact: the additional
life gained from CRT-P, compared with OPT alone, was a
median of 1.69 years for 40 year olds and only 0.54 years for
80 year olds. The additional life gained from CRT-D was 3.08
and 1.23 years, respectively. The addition of a deﬁbrillation
capacity to the device makes an important difference at all ages.
8
For 50 year olds, the proportional increase in overall median sur-
vival was 23% for CRT-P and 41% for CRT-D, compared with
OPT. Other studies have shown that outcome of CRT also
depends upon the NYHA class prior to implantation,
9–11 the
aetiology of the heart failure,
12 and the atrial rhythm.
13
In observational studies, the criterion for survival with CRT has
arbitrarily been set at 1 year of life following implantation.
14–16
Rather than adopting such arbitrary cut-offs, patients could be con-
sidered ‘prognostic responders’ to CRT if their actual survival
matches that expected from modelling analyses, taking into
account patient- and device-related variables. This methodology,
which is yet to be applied, is anticipated to be more precise than
using the same arbitrary cut-offs for all patients.
Response
It is often quoted that CRT has a ‘non-responder’ rate of up to
30%, implying that a responder rate of anything lower than 100%
is unsatisfactory. Similar ﬁgures, however, emerge for drug
therapy if the same approach is adopted. In the results of the
Cooperative North Scandinavian Enalapril Survival Study (CON-
SENSUS), 46.7% of patients treated with enalapril improved by
 1 NYHA class.
17 In the Cardiac Insufﬁciency Bisoprolol Study
(CIBIS), 21% of patients treated with bisoprolol improved by  1
NYHA class.
18 In the Randomized Aldactone Evaluation Study
(RALES), 41% of patients treated with spirinolactone improved
by  1 NYHA class.
19 Accordingly, the ‘non- responder’ rates in
these studies were 53.3% for enalapril, 79% for bisoprolol, and
59% for spironolactone. To quantify the true additional effect of
a treatment, it is necessary to compare the new therapy with con-
trols. Adopting an improvement by  1 NYHA class as the deﬁ-
nition of response, the ‘responder’ rate for placebo was 21.8% in
the CONSENSUS study, 15% in the CIBIS study, and 33% in the
RALES study. Accordingly, the response to treatment, compared
with placebo, was 24.9% for enalapril, 6% for bisoprolol, and 8%
for spironolactone.
The symptomatic response to CRT can be quantiﬁed in random-
ized, controlled trials, but what should be considered to be an ade-
quate response to CRT in individual patients? With reference to
the CARE-HF study, CRT was associated with a reduction in
NYHA class from 3.06 at baseline to 2.1 at 90 days post-
implantation.
5 With respect to quality of life, the COMPANION
study showed an improvement by 8.8% with CRT-P, 9.3% with
CRT-D, and 3.7% with medical therapy alone.
6 Therefore, a
reduction by approximately one NYHA class and an improvement
in quality of life by 5 to 6% is what should CRT-P or CRT-D be
expected to achieve in the ‘average’ patient.
Discordance between outcome
and response
A favourable symptomatic response to a treatment does not
necessarily parallel a favourable outcome. At one extreme, pallia-
tive treatments improve symptoms but do not prolong survival.
At the other, chemotherapy for cancer prolongs survival, but
causes symptoms and worsens quality of life. It should also be con-
sidered that, if given the choice, some patients prefer symptomatic
beneﬁt to prognostic beneﬁt, particular if they are severely limited
by symptoms.
As for most treatments for heart failure, symptomatic and prog-
nostic beneﬁts from CRT are not necessarily concordant. This was
suggested by Yu et al.,
20 who found similar improvements in
NYHA class, 6 min walk distance and quality of life at 3–6
months in survivors and non-survivors treated by CRT. These ﬁnd-
ings raise problems in clinical practice. For example, should CRT be
modiﬁed or withdrawn in a patient who has improved symptoma-
tically but in whom a surrogate measure of outcome predicts a
shortened survival? So far, this question is unanswered.
Surrogate markers of outcome
A surrogate endpoint should be a true predictor of disease, not
reﬂection of a co-variable.
21 To be clinically useful, a surrogate
measure of outcome must be measurable and reproducible by
different observers and by different centres. It should be reliable,
available, and easily quantiﬁable. The relationship between a surro-
gate and the true endpoint should be also validated internally,
22
within the population from which it is derived, and externally by
other centres. In addition, P-values should not be considered to
be the sole arbiter in a study. A P , 0.05 does not mean that
the sample size is adequate, that the effect size is clinically mean-
ingful, or that the parameter in question has discriminatory
ability.
23 Diagnostic utility should be tested using Bayesian analyses.
Cut-offs should be sensitive and speciﬁc (.90% for both), with a
clear distinction between what is normal or abnormal.
In an ideal world, the surrogate endpoint is mechanistically
linked to the true endpoint via a single pathway and the surrogate
.................................... ........................
................................................................................
Table 1 Survival from CRT-P and CRT-D over a
patients’ lifetime
Age
b Survival Additional life
a
OPT CRT-P CRT-D CTR-P CRT-D
30 7.31 9.00 10.39 1.69 3.08
40 7.23 8.92 10.31 1.69 3.08
50 7.15 8.76 10.08 1.62 2.92
60 6.15 7.15 8.00 1.00 1.85
70 4.46 5.39 5.85 0.92 1.39
80 3.08 3.77 4.31 0.54 1.23
90 2.31 2.69 2.92 0.39 0.62
Overall 3.77 4.62 5.15 0.85 1.39
All values are expressed as medians (years).
Reproduced with permission from the Peninsula Technology Assessment Group.
8
aRefers to survival advantage over optimum medical therapy alone (OPT).
bAge at the time of implantation.
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is affected by the intervention. In practice, however, the pathophy-
siological processes linking the cause and the surrogate are mani-
fold, as are the processes linking the surrogate endpoint and the
true endpoint (Figure 1). These complex interactions between bio-
logical variables often underlie the difﬁculty in identifying reliable
surrogate endpoints.
Reverse left ventricular remodelling
Cardiac remodelling is the ﬁnal common pathway of chamber dila-
tation and failure that occurs after myocardial infarction, pressure
overload, inﬂammatory muscle disease, idiopathic dilated
cardiomyopathy, or volume overload.
24 Left ventricular remodel-
ling has been linked to poor long-term prognosis in patients with
heart failure.
24–26 Reverse LV remodelling, on the other hand,
has been demonstrated with drugs that are known to beneﬁt
patients with heart failure, such as angiotensin converting
enzyme (ACE) inhibitors
24,27–29 and beta-blockers.
29 Reductions
in LV end-systolic volume (LVESV) appears to be the most useful
measure of reverse remodelling.
26
Numerous studies have shown signiﬁcant reduction in LVESV
after CRT.
20,30–32 Such reductions are evident as early as
1 month post-implantation,
33 and are sustained at 29 months.
5
Further support for a causative link between CRT and reverse
LV remodelling is suggested by the ﬁnding of LV dilatation when
CRT is withdrawn.
34 The value of reverse LV remodelling in discri-
minating prognostic ‘responders’ and ‘non-responders’ to CRT was
explored in a study of 141 patients, in which a reduction in LVESV
 9.5% 3 to 6 months post-implantation was identiﬁed as a predic-
tor of all-cause (P ¼ 0.0003) and cardiovascular (P , 0.0001) mor-
tality.
20 There is, in addition, evidence to indicate that the
magnitude of reverse LV remodelling relates to the clinical
outcome. In this respect, Ypenburg et al.
35 found that in patients
undergoing CRT, all-cause mortality was 3% in patients with a
LVESV reduction of  30% and 21% in patients with a LVESV
reduction between 0 and 14%. This goes some way towards satis-
fying another desirable characteristic of surrogate endpoints,
namely, that they should relate linearly to the true endpoint.
36
On the basis of the above, reverse LV remodelling is a promising
surrogate measure of outcome after CRT. Cut-offs of reverse LV
remodelling must, however, clearly differentiate between good
and poor outcome. They must, therefore, withstand the rigour
of Bayesian analyses. One of the few studies to employ this meth-
odology showed that a reduction in LVESV  9.5% predicted all-
cause mortality with a sensitivity of 70% and a speciﬁcity of 70%,
and cardiovascular mortality with a sensitivity of 87% and a speci-
ﬁcity of 69% (Figure 2).
20 While these ﬁgures compare favourably
with other biomarkers, it must be noted that a sensitivity of 70%
means that 30% of patients, who beneﬁt prognostically from
CRT, are wrongly classiﬁed as ‘non-responders’. A speciﬁcity of
69% means that 31% of patients, who do not beneﬁt prognosti-
cally, are wrongly classiﬁed as ‘responders’. With this discrimina-
tory ability, it would appear that reduction in LVESV is of limited
value in discriminating between ‘responders’ and ‘non-responders’
after CRT. As a further limitation of studies of LV remodelling in
relation to CRT, none has used the statistical methodology of
internal and external validation.
22
Although reverse LV remodelling relates to outcome, it does
not relate to symptomatic response. In a study of 141 patients
undergoing CRT, Yu et al.
20 found no relationship between
reduction in LVESV and changes in NYHA class, 6 min walk dis-
tance, or quality of life score after CRT. Likewise, Ypenburg
et al.
35 found similar improvement in NYHA class, quality of life
score, and 6 min walk distance in patients exhibiting  15%
reduction in LVESV compared with those exhibiting a reduction
in LVESV of ,14%. Laﬁtte et al.
37 showed that 63% of patients,
who did not show a  15% reduction in LVESV following CRT,
nevertheless made clinical improvement. A clinician may, therefore,
encounter a patient, who has improved symptomatically after CRT,
Figure 1 Relationship between disease processes, interven-
tions, surrogate endpoints, and true clinical outcome. (A) The
ideal situation, which offers the greatest potential for the surro-
gate to be valid; (B) the surrogate is not in the aetiological
pathway of the disease; (C) the intervention affects only the
pathway mediated through the surrogate, but there are other
aetiological pathways; (D) the intervention does not affect the
surrogate; (E) the mechanism of action of the intervention is
independent of the disease process. Dotted lines represent
other possible mechanisms of action. Adapted with permission
from Fleming TR and DeMets DL.
84
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whether the absence of reverse remodelling, even on the back-
ground of clinical improvement, should prompt further interven-
tion, e.g. atrioventricular and ventricular-ventricular optimization,
lead repositioning or withdrawal of therapy.
The discordance between symptoms and reverse LV remodel-
ling after CRT is not unexpected, given that CRT acts via multiple
pathways. Diastolic ventricular interaction, which is demonstrable
in patients with heart failure,
38 is relieved by CRT.
39 In addition,
CRT reduces functional mitral regurgitation,
40 an effect which is
not wholly dependent on reverse LV remodelling.
41 Blood
ﬂow,
42 heart failure aetiology,
43 location of myocardial scarring,
44
and atrial rhythm
13 may also inﬂuence the outcome of CRT. In
addition, it has been shown that withdrawal of CRT in patients
who had exhibited progressive LV remodelling was associated
with a reduction in blood pressure and cardiac output
45
(Figure 3). This suggests that CRT confers a favourable haemo-
dynamic proﬁle, even on the background of progressive cardiac
remodelling.
Left ventricular ejection fraction
The notion that LV systolic function relates to the prognosis of
heart failure is mechanistically attractive. In this respect, the
Vasodilator-Heart Failure Trials (V-HeFT I and II) identiﬁed LVEF,
measured using radionuclide imaging, as a predictor of mortality
in male patients with heart failure.
46 Improvements in LVEF with
Figure 2 Reciever-operating curves for predicting all-cause (A)
and cardiovascular (B) mortality by LV reverse remodelling, as
reﬂected by the reduction in LVESV (dark line) and LVEDV
(light line). Reproduced with permission from Yu CM, et al.
20
Figure 3 Acute haemodynamic changes in patients with
CRT-on and CRT-off. Changes pertain to patients with advanced
decompensated heart failure who had undergone CRT implan-
tation at least 3 months prior to testing. A signiﬁcant worsening
of haemodynammics was observed immediately after CRT was
programmed off. Reproduced with permission from Mullens
et al.
45
What is treatment success in CRT? v61treatment have also been linked to improved prognosis.
46,47 In
some studies, however, drugs, which are known to prolong survi-
val, such as carvedilol
48 and enalapril
49 do not signiﬁcantly alter
LVEF (Figure 4). Conversely, bucindolol does increase LVEF, but
does not prolong survival.
50
In the CARE-HF trial, LVEF at 3 months increased by 4.7% in the
CRT-P arm, compared with 0.3% in OPT arm.
51 In multivariate
analyses, however, improvements in LVEF did not emerge as an
independent predictor of outcome. The demonstration of an
increase in LVEF by CRT, therefore, does not endorse the use of
LVEF as a predictor of beneﬁt from CRT. It should also noted
that, in patients with heart failure, LVEF relates poorly to symp-
toms.
52 Furthermore, the value of LVEF in monitoring patients
with heart failure has not been addressed by randomized studies,
nor has it been validated, with regard to CRT, nor any other treat-
ment. On this basis, echocardiographically derived LVEF is an unli-
kely surrogate measure of outcome in CRT patients.
Other echocardiographic variables
On the basis that cardiac dyssynchrony is the substrate for effective
CRT, some echocardiographic studies have adopted dyssynchrony
measures, such as the septal-to-posterior wall motion delay and
the interventricular mechanical delay, as study endpoints.
53 Yet,
these measures have been proven not to relate to clinical improve-
ment after CRT.
54 No studies have validated whether correction of
dyssynchrony translates into an improved response or outcome
after CRT.
Haemodynamics
As for LVEF, improvements in the haemodynamic proﬁle should,
intuitively, qualify as a measure of response and outcome after
CRT. While, undoubtedly, CRT causes a haemodynamic improve-
ment in the acute setting,
2,3 no studies have explored whether this
is predictive of long-term response or outcome. Treatments,
which improve cardiac function, do not necessarily lead to a prog-
nostic beneﬁt. A trial comparing hydralazine and nitrates with an
ACE-inhibitor showed that, despite similar haemodynamic
effects, mortality was lower with the ACE inhibitor.
55 On this
basis, haemodynamic variables cannot be used as predictors of
long-term response or outcome after CRT.
Peak oxygen uptake
Peak VO2 is regarded as the gold standard prognostic marker in
patients with heart failure. One of the earliest studies to analyse
peak VO2 in relation to outcome in patients with heart failure
was that of Mancini et al.
56 According to the study protocol,
patients with a peak VO2 .14 mL/kg/min were denied transplan-
tation, whereas those with a peak VO2   14 mL/kg/min were
offered transplantation. The study demonstrated that peak VO2
could be used to identify patients in whom cardiac transplantation
could be safely delayed. However, as mortality and transplantation
were inﬂuenced by the study protocol, the ﬁndings cannot be
taken as validation of peak VO2 as a predictor of mortality in
patients with heart failure. In a similar study of patients referred
for cardiac transplantation, Aaronson et al.
57 found that normalized
peak VO2 predicted survival, but the area under the receiver-
operator characteristic curve (ROC) was only 0.66. In a study of
644 patients, Myers et al.
58 found that peak VO2 predicted mor-
tality, but the ROC area was only 0.64 (Figure 5). In addition,
these authors could not identify an optimal cut-off point for pre-
dicting survival. Several studies have shown that peak VO2 does
not predict survival in patients with heart failure.
59–61 With
regard to peak VO2 in relation to symptoms, Wilson et al.
62
found no relation between peak VO2 and quality of life, and only
a weak correlation between peak VO2 and a dyspnoea/fatigue
index. In this study, up to 45% of patients with a peak VO2
,14 mL/kg/min had few or no exertional symptoms. It would
appear, therefore, that peak VO2 is not a reliable measure of
Figure 4 Effect on ejection fraction of carvedilol and placebo in
the Australia-New Zealand (ANZ) carvedilol study,
48 enalapril
and placebo in the SOLVD study.
49
Figure 5 Receiver-operating curves for peak VO2 in relation to
3 year survival. The area under the curve was signiﬁcantly greater
for peak VO2 than for age and ejection fraction (P , 0.05).
Reproduced with permission from Myers et al.,
58 EF, left ventricu-
lar ejection fraction.
P.W.X. Foley et al. v62response or a predictor of outcome in unpaced patients with heart
failure.
An increase in peak VO2, ranging from 0.6
63 to 1.4 mL/kg/min
has been reported in relation to CRT.
64 Although this conﬁrms
that CRT has an effect upon cardiopulmonary and metabolic
status, it does not equate to validation of peak VO2 as a surrogate
measure of response or outcome. As a practical issue, temporal
changes in peak VO2 in individual patients are highly unpredict-
able.
65 This should be taken into account in interpreting the ﬁnd-
ings of studies such as RethinQ study, in which, interestingly,
patients with narrow QRS complexes undergoing CRT exhibited
an improvement in NYHA class, but not in peak VO2.
66
Walk distance
The 6 min walk test (6-MWT) has been adopted as a measure of
response to CRT in a number of studies. In a study of 1077 patients
with heart failure, Ingle et al.
67 found a negative correlation
(r ¼ 20.55; P ¼ 0.0001) between changes in symptoms and
changes in 6-MWT distance (i.e. a reduced 6-MWT distance is
associated with reduced symptom severity at follow-up). On this
basis, the 6-MWT provides a reproducible
68 measure of sympto-
matic status in patients with heart failure. In a systematic review,
the 6-MWT distance was shown to concur with changes in heart
failure symptoms, particularly in the context of CRT.
69
As well as providing an additional measure of symptomatic
status, 6-MWT distance has been shown to relate to survival in
unpaced patients with heart failure.
60,70 In patients undergoing
CRT, pre-implant a 6-MWT distance ,225 m has been shown
independently to predict cardiovascular mortality.
71 Further
studies are needed to validate that the absolute 6-MWT distance
or change from baseline after implantation also translates into
poor outcome.
Neuroendocrine data
The observation that circulating natriuretic peptide levels change
with drug treatment
72,73 raises the possibility that they may be
good surrogate markers of outcome after CRT. In a study of
50 patients undergoing CRT, Pitzalis et al.
74 observed that at
1 month post-implantation, brain natriuretic peptide (BNP) was
lower in patients who had experienced no progression of heart
failure, compared with those who did. Further data from the
CARE-HF study showed that N-terminal (NT)-pro-BNP 3 month
post-implantation predicted long-term outcome (HR 5.7 for
patients in the highest tertile compared with those in the lowest
tertile).
51
Although natriuretic peptides relate to the clinical outcome of
CRT, their very high variability is likely to compromise their use
as surrogate markers of outcome during clinical follow-up. In
healthy individuals, serial changes of up to 92% for NT pro-BNP
and up to 168% for BNP have been reported.
75 In patients with
heart failure, the intraindividual coefﬁcient of variation can be as
high as 35% from week to week.
76 To be useful as a marker of
response, one must deﬁne what reduction in natriuretic peptides
post-implantation relates accurately to a future survival beneﬁt in
individual patients. To date, however, the magnitude of this
reduction has not been determined, nor validated. Post-implant
changes in natriuretic peptides, therefore, cannot be taken as
reliable surrogate markers of long-term outcome after CRT.
Ventricular arrhythmias
Ventricular ectopy was once considered a surrogate of prognostic
beneﬁt following a myocardial infarction. Drugs which reduce ven-
tricular ectopy, such as ﬂecainide,
77 however, were subsequently
found to shorten survival. Similarly, amiodarone controls ventricu-
lar tachycardia, but has no effect on survival. Early studies showed
that CRT reduces ventricular ectopy
78 and device delivered antita-
chycardia therapy.
79 These ﬁndings may be relevant to those of the
CARE-HF extension study, in which reduction in sudden cardiac
death following CRT was found.
80 Importantly, such an effect
was not apparent after the initial 29 months’ follow-up.
5 It
follows, therefore, that even if ventricular arrhythmias were good
predictors of sudden cardiac death after CRT, they would be unli-
kely to be predictors of survival beneﬁt.
Composite measures
As discussed earlier, single measures are unlikely to be reliable pre-
dictors of the outcome of CRT in the complex syndrome of heart
failure. The rationale for using composite measures stems from the
fact that heart failure has many effects: it causes death, hospitaliz-
ation, exercise intolerance, breathlessness, and a worsening in
quality of life. The attraction of a composite endpoint, or score,
is that it allows the reduction of a disease’s varied effects into a
single, measurable parameter. By strengthening the capacity to
pick out weaker signals from the background noise of sampling
error, combined endpoints improve the decisiveness of a clinical
trial.
23 In clinical practice, composite clinical scores
81 could
include variables which, together, amount to a clinically meaningful
measure. The difﬁculty lies in choosing what to measure and in
deciding on the relative importance of each measure.
82 For
example, should a reduction in LVESV be treated with equal
importance (or weighting) as an improvement in NYHA class, or
avoidance of hospitalization, or death? The 9th Clinical Trialists
Workshop of the US National Institutes of Health and other regu-
latory bodies concluded that standards for weighting composite
scores were needed; that consensus was needed to deﬁne a clini-
cally meaningful effect of composite scores, and that the value of
the ‘trade-off’ position between components of composite
scores needs to be deﬁned.
83 These issues are yet to be addressed
in the ﬁeld of CRT. Arguably, they should be a priority for regulat-
ory bodies.
Conclusions
In summary, CRT has revolutionized the treatment of selected
patients with heart failure. Although reverse LV remodelling is a
promising surrogate of outcome after CRT, one should consider
that volumetric ‘non-responders’ may nevertheless experience
symptomatic beneﬁt. On the other hand, patients who beneﬁt
symptomatically may not necessarily derive a prognostic beneﬁt.
As for most heart failure therapies, reliable measures of response
to CRT in individual patients are yet to emerge. Composite
measures may hold the key. Such measures must be validated
against the survival and symptomatic beneﬁts that are to be
What is treatment success in CRT? v63expected from therapy in individual patients, on the basis of ran-
domized, controlled trials. In addition, composite clinical endpoints
must reﬂect the relative importance of response and outcome
beneﬁts, as judged by patients, not doctors. Until this is established,
the terms ‘responder’ and ‘non-responder’ to CRT have little
meaning in clinical practice.
Conﬂict of interest: none declared.
Funding
The Open Access publication charges for this article were paid
for from research funds provided by the Heart of England NHS
Foundation Trust.
References
1. Cazeau S, Ritter P, Bachdach S, Lazarus A, Limousin M, Henao L et al. Four
chamber pacing in dilated cardiomyopathy. Pacing Clin Electrophysiol 1994;17:
1974–9.
2. Leclercq C, Cazeau S, Le Breton H, Ritter P, Mabo P, Gras D et al. Acute hemo-
dynamic effects of biventricular DDD pacing in patients with end stage heart
failure. J Am Coll Cardiol 1998;32:1825–31.
3. Auricchio A, Stellbrink C, Block M, Sack S, Vogt J, Bakker P et al., For the Guidant
Congestive Heart Failure Research Group. Effect of pacing chamber and atrioven-
tricular delay on acute systolic function of paced patients with congestive heart
failure. Circulation 1999;99:2993–3001.
4. Cazeau S, Leclercq C, Lavergene T, Walker S, Varma C, Linde C et al., for the
Multistimulation in Cardiomyopathies (MUSTIC) Study Investigators. Effects of
multisite biventricular pacing in patients with heart failure and interventricular
conduction delay. N Engl J Med 2001;344:873–80.
5. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L
et al., for the Cardiac Resynchronization-Heart Failure (CARE-HF) study investi-
gators. The effect of cardiac resynchronization on morbidity and mortality in
heart failure. N Engl J Med 2005;352:1539–49.
6. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass D, De Marco T et al., for the
Comparison of Medical Therapy, Pacing and Deﬁbrillation in Heart Failure (COM-
PANION) Investigators Cardiac resynchronization therapy with or without an
implantable deﬁbrillator in advanced heart failure. N Eng J Med 2004;350:
2140–50.
7. International Conference in Harmonisation of Technical Requirements for Regu-
lation of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline.
Statistical principles for clinical trials (ICH 9).
8. Barnett D, Phillips S, Longson C. Cardiac resynchronisation therapy for the treat-
ment of heart failure: NICE technology appraisal guidance. Heart 2007;93:
1134–5.
9. Gasparini M, Lunati M, Santini M, Tritto M, Curnis A, Bocchiardo M et al. Long-
term survival in patients treated with cardiac resynchronization therapy: a
3-year follow-up study from the InSync/InSync ICD Italian Registry. Pacing Clin
Electrophysiol 2006;29:S2–S10.
10. Kronborg MB, Mortensen PT, Kirkfeldt RE, Nielsen JC. Very long term follow-up
of cardiac resynchronization therapy: clinical outcome and predictors of mor-
tality. Eur J Heart Fail 2008;10:796–801.
11. de Sisti A, Toussaint JF, Lavergne T, Ollitrault J, Abergel E, Paziaud O et al. Deter-
minants of mortality in patients undergoing cardiac resynchronization therapy:
baseline clinical, echocardiographic, and angioscintigraphic evaluation prior to
resynchronization. Pacing Clin Electrophysiol 2005;28:1260–70.
12. Molhoek SG, Bax JJ, van Erven L, Bootsma M, Boersma E, Steendijk P et al. Com-
parison of beneﬁts from cardiac resynchronization therapy in patients with
ischemic cardiomyopathy versus idiopathic dilated cardiomyopathy. Am J Cardiol
2004;93:860–3.
13. Gasparini M, Auricchio A, Metra M, Regoli F, Fantoni C, Lamp B et al. Long-term
survival in patients undergoing cardiac resynchronization therapy: the importance
of performing atrio-ventricular junction ablation in patients with permanent atrial
ﬁbrillation. Eur Heart J 2008;29:1644–52.
14. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JW, Garrigue S et al. Cardiac
resynchronization therapy: Part 2–issues during and after device implantation and
unresolved questions. J Am Coll Cardiol 2005;46:2168–82.
15. Bleeker GB, Bax JJ, Fung JW, van der Wall EE, Zhang Q, Schalij MJ et al. Clinical
versus echocardiographic parameters to assess response to cardiac resynchroni-
zation therapy. Am J Cardiol 2006;97:260–3.
16. Foley PW, Chalil S, Khadjooi K, Jordan P, Smith RE, Frenneaux MP et al. Effects of
cardiac resynchronization therapy in patients unselected for mechanical
dyssynchrony. Int J Cardiol 2009. Epub ahead of print 24 February 2009, doi:
10.1016/j.ijcard.2009.01.044.
17. Effects of enalapril on mortality in severe congestive heart failure. Results of the
Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The
CONSENSUS Trial Study Group. N Engl J Med 1987;316:1429–35.
18. A randomized trial of beta-blockade in heart failure. The Cardiac Insufﬁciency
Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 1994;
90:1765–73.
19. Pitt B, Zannad F, Remme WJ et al., for the Randomized Aldactone Evaluation
Study Investigators. The effect of spironolactone on morbidity and mortality in
patients with severe heart failure. N Engl J Med 1999;341:709–17.
20. Yu CM, Bleeker GB, Fung JW, Schalij MJ, Zhang Q, van der Wall EE et al. Left ven-
tricular reverse remodeling but not clinical improvement predicts long-term sur-
vival after cardiac resynchronization therapy. Circulation 2005;112:1580–6.
21. Prentice R. Surrogate endpoints in clinical trials: deﬁnition and operational cri-
teria. Stat Med 1989;8:431–40.
22. Harrell FJ, Lee K, Califf R, Pryor D, Rosati R. Regression modelling strategies for
improved prognostic prediction. Stat Med 1984;3:143–52.
23. Moye ´ L. Statistical Reasoning in Medicine. New York, NY: Springer; 2006.
24. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling—concepts and clinical impli-
cations: a consensus paper from an international forum on cardiac remodeling.
Behalf of an International Forum on Cardiac Remodeling. J Am Coll Cardiol
2000;35:569–82.
25. Gaudron P, Eilles C, Kugler I, Ertl G. Progressive left ventricular dysfunction and
remodeling after myocardial infarction. Potential mechanisms and early predic-
tors. Circulation 1993;87:755–63.
26. White HD, Norris RM, Brown MA et al. Left ventricular end-systolic volume as
the major determinant of survival after recovery from myocardial infarction. Cir-
culation 1987;76:44–51.
27. Beckwith C, Munger MA. Effect of angiotensin-converting enzyme inhibitors on
ventricular remodeling and survival following myocardial infarction. The Ann Phar-
macother 1993;27:755–66.
28. Konstam MA. Reliability of ventricular remodeling as a surrogate for use in con-
junction with clinical outcomes in heart failure. Am J Cardiol 2005;96:867–71.
29. Cohn JN. Remodeling as an end-point in heart failure therapy. Cardiovasc Drugs
Ther 2004;18:7–8.
30. Rao RK, Kumar UN, Schafer J, Viloria E, De Lurgio D, Foster E. Reduced ventri-
cular volumes and improved systolic function with cardiac resynchronization
therapy: a randomized trial comparing simultaneous biventricular pacing, sequen-
tial biventricular pacing, and left ventricular pacing. Circulation 2007;115:2136–44.
31. St John Sutton MG, Plappert T, Abraham WT, Smith AL, DeLurgio DB, Leon AR
et al., for the Multicenter InSync Randomized Clinical Evaluation (MIRACLE)
Study Group. Effect of cardiac resynchronization therapy on left ventricular size
and function in chronic heart failure. Circulation 2003;107:1985–90.
32. Abraham WT, Hayes DL. Cardiac resynchronization therapy for heart failure. Cir-
culation 2003;108:2596–603.
33. Linde C, Leclercq C, Rex S, Garrigue S, Lavergne T, Cazeau S et al. Long-term
beneﬁtsofbiventricularpacingincongestiveheartfailure:resultsfromtheMUltisite
STimulation In Cardiomyopathy (MUSTIC) study. J Am Coll Cardiol 2002;40:111–8.
34. Yu C-M, Chau E, Sanderson JE, Fan K, Tang M-O, Fung W-H et al. Tissue Doppler
echocardiographic evidence of reverse remodeling and improved synchronicity by
simultaneously delaying regional contraction after biventricular pacing therapy in
heart failure. Circulation 2002;105:438–45.
35. Ypenburg C, van Bommel RJ, Borleffs CJ, Bleeker GB, Boersma E, Schalij MJ et al.
Long-term prognosis after cardiac resynchronization therapy is related to the
extent of left ventricular reverse remodeling at midterm follow-up. J Am Coll
Cardiol 2009;53:483–90.
36. Anand IS, Florea VG, Fisher L. Surrogate end points in heart failure. J Am Coll
Cardiol 2002;39:1414–21.
37. Laﬁtte S, Reant P, Zaroui A, Donal E, Mignot A, Bougted H et al. Validation of an
echocardiographic multiparametric strategy to increase responder patients after
cardiac resynchronization: a multicentre study. Eur Heart J; advance access publi-
cation 9 January 2009, doi: 10.1093/eurheartj/ehn582.
38. Atherton JJ, Moore TD, Lele SS, Thomson HL, Galbraith AJ, Belenkie I et al. Dias-
tolic ventricular interaction in chronic heart failure. Lancet 1997;349:1720–4.
39. Bleasdale RA, Turner MS, Mumford CE, Steendijk P, Paul V, Tyberg JV et al. Left
ventricular pacing minimizes diastolic ventricular interaction, allowing improved
preload-dependent systolic performance. Circulation 2004;110:2395–400.
40. Ypenburg C, Lancellotti P, Tops LF, Bleeker GB, Holman ER, Pierard LA et al.
Acute effects of initiation and withdrawal of cardiac resynchronization therapy
on papillary muscle dyssynchrony and mitral regurgitation. J Am Coll Cardiol
2007;50:2071–7.
41. Sadeghpour A, Abtahi F, Kiavar M, Esmaeilzadeh M, Samiei N, Ojaghi SZ et al.
Echocardiographic evaluation of mitral geometry in functional mitral regurgitation.
J Cardiothoracic Surg 2008;3:54.
P.W.X. Foley et al. v6442. Lindner O, Vogt J, Kammeier A, Wielepp P, Holzinger J, Baller D et al. Effect of
cardiac resynchronization therapy on global and regional oxygen consumption
and myocardial blood ﬂow in patients with non-ischaemic and ischaemic cardio-
myopathy. Eur Heart J 2005;26:70–6.
43. Wikstrom G, Blomstrom-Lundqvist C, Andren B, Lonnerholm S, Blomstrom P,
Freemantle N et al. The effects of aetiology on outcome in patients treated
with cardiac resynchronization therapy in the CARE-HF trial. Eur Heart J 2009;
30:782–8.
44. Chalil S, Foley P, Muyhaldeen S, Patel K, Yousef Z, Smith R et al. Late gadolinium
enhancement-cardiovascular magnetic resonance as a predictor of response to
cardiac resynchronization therapy in patients with ischaemic cardiomyopathy.
Europace 2007;9:1031–7.
45. Mullens W, Verga T, Grimm RA, Starling RC, Wilkoff BL, Tang WH. Persistent
hemodynamic beneﬁts of cardiac resynchronization therapy with disease pro-
gression in advanced heart failure. J Am Coll Cardiol 2009;53:600–7.
46. Cohn JN, Johnson GR, Shabetai R, Loeb H, Tristani F, Rector T et al. Ejection frac-
tion, peak exercise oxygen consumption, cardiothoracic ratio, ventricular arrhyth-
mias, and plasma norepinephrine as determinants of prognosis in heart failure.
The V-HeFT VA Cooperative Studies Group. Circulation 1993;87:VI5–VI16.
47. Gradman A, Deedwania P, Cody R, Massie B, Packer M, Pitt B et al. Predictors of
total mortality and sudden death in mild to moderate heart failure. Captopril-
Digoxin Study Group. J Am Coll Cardiol 1989;14:564–70. Discussion 571–582.
48. Doughty RN, Whalley GA, Gamble G, MacMahon S, Sharpe N. Left ventricular
remodeling with carvedilol in patients with congestive heart failure due to
ischemic heart disease. Australia-New Zealand Heart Failure Research Collabora-
tive Group. J Am Coll Cardiol 1997;29:1060–6.
49. Effect of enalapril on survival in patients with reduced left ventricular ejection
fraction and congestive heart failure. The SOLVD Investigators. N Engl J Med
1991;325:293–302.
50. The Beta-Blocker Evaluation of Survival Trial Investigators. A Trial of the Beta-
Blocker Bucindolol in Patients with Advanced Chronic Heart Failure. N Engl J
Med 2001;344:1659–67.
51. Cleland J, Freemantle N, Ghio S, Fruhwald F, Shankar A, Marijanowski M et al. Pre-
dicting the long-term effects of cardiac resynchronization therapy on mortality
from baseline variables and the early response a report from the CARE-HF
(Cardiac Resynchronization in Heart Failure) Trial. J Am Coll Cardiol 2008;52:
438–45.
52. Marantz PR, Tobin JN, Wassertheil-Smoller S, Steingart RM, Wexler JP, Budner N
et al. The relationship between left ventricular systolic function and congestive
heart failure diagnosed by clinical criteria. Circulation 1988;77:607–12.
53. Bax JJ, Abraham T, Barold SS, Breithardt OA, Fung JWH, Garrigue S et al. Cardiac
resynchronization therapy: part 1–issues before device implantation. J Am Coll
Cardiol 2005;46:2153–67.
54. Chung E,LeonA,Tavazzi L,Sun J,NihoyannopoulosP,MerlinoJ etal.Resultsofthe
Predictors of Response to CRT (PROSPECT) Trial. Circulation 2008;117:2608–16.
55. Fonarow GC, Chelimsky-Fallick C, Stevenson LW, Luu M, Hamilton MA,
Moriguchi JD et al. Effect of direct vasodilation with hydralazine versus
angiotensin-converting enzyme inhibition with captopril on mortality in advanced
heart failure: the Hy-C trial. J Am Coll Cardiol 1992;19:842–50.
56. Mancini DM, Eisen H, Kussmaul W, Mull R, Edmunds LH Jr, Wilson JR. Value of
peak exercise oxygen consumption for optimal timing of cardiac transplantation
in ambulatory patients with heart failure. Circulation 1991;83:778–86.
57. Aaronson KD, Mancini DM. Is percentage of predicted maximal exercise
oxygen consumption a better predictor of survival than peak exercise oxygen
consumption for patients with severe heart failure? J Heart Lung Transplant
1995;14:981–9.
58. Myers J, Gullestad L, Vagelos R, Do D, Bellin D, Ross H et al. Cardiopulmonary
exercise testing and prognosis in severe heart failure: 14 mL/kg/min revisited.
Am Heart J 2000;139:78–84.
59. Franciosa JA. Why do patients with heart failure die? Hemodynamic and func-
tional determinants of survival. Ciculation 1987;75:IV20–7.
60. Rostagno C, Olivo G, Comeglio BV, Banchelli M, Galanti G, Gensini G. Prognostic
value of 6-minute walk corridor test in patients with mild to moderate heart
failue: comparison with other methods of functional evaluation. Eur J Heart Fail
2003;5:247–52.
61. Shakar SF, Lowes BD, Lindenfeld J, Zolty R, Simon M, Robertson AD et al. Peak
oxygen consumption and outcome in heart failure patients chronically treated
with beta-blockers. J Card Fail 2004;10:15–20.
62. Wilson JR, Rayos G, Yeoh TK, Gothard P, Bak K. Dissociation between exertional
symptoms and circulatory function in patients with heart failure. Circulation 1995;
92:47–53.
63. Zardini M, Tritto M, Bargiggia G et al. The InSync Italian registry: analysis of clinical
outcome and considerations on the selection of candidates to left ventricular
resynchronization. Eur Heart J Suppl 2000;2:J16–22.
64. Bradley DJ, Bradley EA, Baughman KL, Berger RD, Calkins H, Goodman SN et al.
Cardiac resynchronization and death from progressive heart failure: a
meta-analysis of randomized controlled trials. JAMA 2003;289:730–40.
65. Lamp B, Vogt J, Schmidt H, Horstkotte D. Impact of cardiopulmonary exercise
testing on patient selection for cardiac resynchronisation therapy. Eur Heart J
2004;6:D5–9.
66. Beshai J, Grimm R, Nagueh S, Baker J, Beau S, Greenberg S et al., for the RethinQ
Study Investigators. Cardiac-resynchronization therapy in heart failure with
narrow QRS complexes. N Eng J Med 2007;357:2461–71.
67. Ingle L, Shelton RJ, Rigby AS, Nabb S, Clark AL, Cleland JG. The reproducibility
and sensitivity of the 6-min walk test in elderly patients with chronic heart
failure. Eur Heart J 2005;26:1742–51.
68. Demers C, McKelvie RS, Negassa A, Yusuf S. Reliability, validity, and responsive-
ness of the six-minute walk test in patients with heart failure. Am Heart J 2001;
142:698–703.
69. Olsson LG, Swedberg K, Clark AL, Witte KK, Cleland JG. Six minute corridor
walk test as an outcome measure for the assessment of treatment in randomized,
blinded intervention trials of chronic heart failure: a systematic review. Eur Heart J
2005;26:778–93.
70. Bittner V, Weiner DH, Yusuf S, Rogers WJ, McIntyre KM, Bangdiwala SI et al. Pre-
diction of mortality and morbidity with a 6-minute walk test in patients with left
ventricular dysfunction. SOLVD Investigators. JAMA 1993;270:1702–7.
71. Castel MA, Mendez F, Tamborero D, Mont L, Magnani S, Tolosana JM et al. Six-
minute walking test predicts long-term cardiac death in patients who received
cardiac resynchronization therapy. Europace 2009;11:338–42.
72. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ et al. Titration
of vasodilator therapy in chronic heart failure according to plasma brain natriure-
tic peptide concentration: randomized comparison of the hemodynamic and
neuroendocrine effects of tailored versus empirical therapy. Am Heart J 1999;
138:1126–32.
73. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG,
Richards AM. Treatment of heart failure guided by plasma aminoterminal brain
natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126–30.
74. Pitzalis MV, Iacoviello M, Di Serio F, Romito R, Guida P, De Tommasi E et al. Prog-
nostic value of brain natriuretic peptide in the management of patients receiving
cardiac resynchronization therapy. Eur J Heart Fail 2006;8:509–14.
75. Wu AH, Smith A, Wieczorek S, Mather JF, Duncan B, White CM et al. Biological
variation for N-terminal pro- and B-type natriuretic peptides and implications for
therapeutic monitoring of patients with congestive heart failure. Am J Cardiol 2003;
92:628–31.
76. Bruins S, Fokkema MR, Romer JW, Dejongste MJ, van der Dijs FP, van den
Ouweland JM et al. High intraindividual variation of B-type natriuretic peptide
(BNP) and amino-terminal proBNP in patients with stable chronic heart failure.
Clin Chem 2004;50:2052–8.
77. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary
report: effect of encainide and ﬂecainide on mortality in a randomized trial of
arrhythmia suppression after myocardial infarction. N Eng J Med 1989;321:
406–12.
78. Walker S, Levy T, Rex S, Brant S, Allen J, Ilsley C et al. Usefulness of suppression
of ventricular arrhythmia by biventricular pacing in severe congestive cardiac
failure. Am J Cardiol 2000;86:231–3.
79. Higgins SL, Yong P, Sheck D, McDaniel M, Bollinger F, Vadecha M et al., for the
Ventak CHF Investigators. Biventricular pacing diminishes the need for implanta-
ble cardioverter deﬁbrillator therapy. J Am Coll Cardiol 2000;36:824–7.
80. Cleland JGF, Daubert J-C, Erdmann E, Freemantle N, Gras D, Kappenberger L
et al., on behalf of the CARE-HF Investigators. Long-term effects of cardiac
resynchronisation therapy on mortality in heart failure (the CArdiac REsynchro-
nization Heart Failure [CARE-HF] Trial Extension Phase). Eur Heart J 2006;27:
1928–32.
81. Packer M. Proposal for a new clinical end point to evaluate the efﬁcacy of
drugs and devices in the treatment of chronic heart failure. J Card Fail 2001;7:
176–82.
82. Freemantle N, Calvert M. Composite and surrogate outcomes in randomised
controlled trials. Br Med J 2007;334:756–7. (Letter).
83. Cohn J, Cleland JG, Lubsen J, Borer JS, Steg PG, Perelman M et al. Unconventional
end points in cardiovascular clinical trials: should we be moving away from mor-
bidity and mortality? J Card Fail 2009;15:199–205.
84. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being
misled? Ann Intern Med 1996;125:605–13.
What is treatment success in CRT? v65